Author: Neil Canavan

The latest results from the International Breast Cancer Intervention Study – one of the longest studies of its kind – show a nearly 30% reduction in the incidence of disease when women at an elevated risk for developing breast cancer are treated prophylactically with the anti-oestrogen drug tamoxifen.

Already approved for metastatic melanoma, Merck & Co’s Keytruda has shown promising activity for difficult-to-treat triple-negative breast cancer.

Roche’s pictilisib, a pan inhibitor of the PI3 kinase enzyme has failed to improve outcomes when combined with fulvestrant in patients with estrogen receptor positive (ER+) metastatic breast cancer in a mid-stage trial.

A small but significant study of Agios Pharmaceuticals’ AG-221, partnered with Celgene, caused a stir at the American Society of Hematology meeting in San Francisco earlier this week.

There’s nothing like getting a new CAR, in fact, it just might save your life.